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Objectives We investigated the significance of fibrosis detected by late gadolinium enhancement cardiovascular magnetic
resonance for the prediction of major clinical events in hypertrophic cardiomyopathy (HCM).
Background The role of myocardial fibrosis in the prediction of sudden death and heart failure in HCM is unclear with a lack
of prospective data.
Methods We assessed the presence and amount of myocardial fibrosis in HCM patients and prospectively followed them
for the development of morbidity and mortality in patients over 3.1  1.7 years.
Results Of 217 consecutive HCM patients, 136 (63%) showed fibrosis. Thirty-four of the 136 patients (25%) in the fibro-
sis group but only 6 of 81 (7.4%) patients without fibrosis reached the combined primary end point of cardiovas-
cular death, unplanned cardiovascular admission, sustained ventricular tachycardia or ventricular fibrillation, or
appropriate implantable cardioverter-defibrillator discharge (hazard ratio [HR]: 3.4, p  0.006). In the fibrosis
group, overall risk increased with the extent of fibrosis (HR: 1.18/5% increase, p  0.008). The risk of un-
planned heart failure admissions, deterioration to New York Heart Association functional class III or IV, or heart
failure-related death was greater in the fibrosis group (HR: 2.5, p  0.021), and this risk increased as the extent
of fibrosis increased (HR: 1.16/5% increase, p  0.017). All relationships remained significant after multivariate
analysis. The extent of fibrosis and nonsustained ventricular tachycardia were univariate predictors for arrhythmic end
points (sustained ventricular tachycardia or ventricular fibrillation, appropriate implantable cardioverter-defibrillator
discharge, sudden cardiac death) (HR: 1.30, p  0.014). Nonsustained ventricular tachycardia remained an indepen-
dent predictor of arrhythmic end points after multivariate analysis, but the extent of fibrosis did not.
Conclusions In patients with HCM, myocardial fibrosis as measured by late gadolinium enhancement cardiovascular mag-
netic resonance is an independent predictor of adverse outcome. (The Prognostic Significance of Fibrosis Detec-
tion in Cardiomyopathy; NCT00930735) (J Am Coll Cardiol 2010;56:867–74) © 2010 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.010fi
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hypertrophic cardiomyopathy (HCM) is a relatively common
nherited cardiac disorder with a population prevalence of 1 in
00. It is a cause of sudden cardiac death (SCD) and an
mportant cause of heart failure (HF) (1–5). A key mechanism
or adverse outcomes is believed to be myocardial fibrosis—
pathological hallmark of the condition (6). Although myocardial
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f Cardiovascular Magnetic Resonance, University College, London, United King-
om; Department of Cardiovascular Medicine, University College, London, United
ingdom; and ¶R Squared Statistics, London, United Kingdom. Research 2brosis was previously only identifiable by biopsy, advances
n cardiovascular magnetic resonance (CMR) have enabled
ts noninvasive detection and quantification in vivo with
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Myocardial Fibrosis and Risk in HCM September 7, 2010:867–74the late gadolinium enhancement
(LGE) technique (7–10). The pres-
ence of fibrosis on CMR is known
to be associated with the presence of
risk factors for SCD, HF symptoms,
and the occurrence of nonsustained
ventricular tachycardia (NSVT)
(11–16). It remains unclear, how-
ever, whether fibrosis is an inde-
pendent predictor of major ad-
verse events and survival.
Methods
From January 2000 to December
2006, consecutive patients with
HCM referred for CMR at the
Royal Brompton Hospital were
recruited. Reasons for referral in-
cluded diagnostic evaluation,
confirmation of diagnosis, family
screening and assessment of se-
verity. The diagnosis of HCM
was made on the basis of typical
clinical, echocardiographic, and
hemodynamic features, accord-
ing to established criteria (5). We
excluded patients with con-
ounding comorbidities, such as significant coronary artery
isease (50% stenosis) (n  6), previous myocardial
nfarction (n 17), or prior gradient reduction therapy (n 
1). All patients 40 years of age had coronary artery
isease excluded angiographically; in those under 40 years of
ge, angiography was performed according to clinical symp-
oms. The study was approved by the Institutional Ethics
ommittee.
vents data. Patient events were recorded by communica-
ion with patients, their cardiologists, and family physicians.
edical records were reviewed after attendance at outpa-
ient clinics or hospital stay. All patients were directly
ontacted at 3- to 6-month intervals during follow-up. Only
ew events from the time of recruitment were considered in
he primary or secondary outcomes. The time of death was
dentified from the U.K. National Strategic Tracing Service
atabase, and cause of death was confirmed through review
f hospital records, general practitioner records, and the
ffice of National Statistics. No patient was lost to
ollow-up.
MR acquisition. A standard volumes and LGE-CMR
as performed on a dedicated scanner (Siemens Sonata/
vanto 1.5-T, Erlangen, Germany), with full myocardial
overage (17). The LGE images were acquired after intra-
enous gadolinium-diethylenetriamine penta-acetic acid
Bayer-Schering, Berlin, Germany; 0.1 mmol/kg) in iden-
ical short-axis planes to cine images with a breath-hold
Abbreviations
and Acronyms
BSA  body surface area
CI  confidence interval
CMR  cardiovascular
magnetic resonance
FWHM  full width half
maximum
HCM  hypertrophic
cardiomyopathy
HF  heart failure
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LAVi  left atrial volume
index
LGE  late gadolinium
enhancement
LVOTO  left ventricular
outflow tract obstruction
NSVT  nonsustained
ventricular tachycardia
NYHA  New York Heart
Association
SCD  sudden cardiac
deathnversion-recovery gradient echo sequence (18). Inversion cimes were optimized to null normal myocardium with
mages repeated in 2 separate phase-encoding directions to
xclude artifact.
mage analysis. Ventricular function was analyzed with
edicated software (CMRtools, Cardiovascular Imaging
olutions, London) (19,20). All volumes and mass measure-
ents were indexed to body surface area (21). The entire
hort-axis LGE stack of images were analyzed quantita-
ively for LGE extent by 2 independent readers with
ustomized software (MRI-MASS, Medis, Leiden, the
etherlands). The endocardial and epicardial borders were
raced for each short-axis slice. A region of interest (ROI)
veraging 50 mm2 was defined within the normal remote
yocardium in an area with uniform myocardial suppres-
ion free of artifacts. A multipass region-growing algorithm
as used to identify the fibrotic boundaries based on the
full width half maximum” (FWHM) technique, and fibro-
is was expressed as present or absent, and its extent was
uantified as a percentage of total left ventricular mass
22–24).
tatistical analysis. Results are summarized as mean (SD)
r n (%) for continuous and categorical variables, respec-
ively. Comparisons of demographic and clinical character-
stics between fibrosis and no fibrosis groups were made
ith unpaired t tests or chi-square tests for continuous and
ategorical data.
The pre-specified primary end point was the composite of
ardiovascular death, unplanned cardiovascular hospital
tay, sustained ventricular tachycardia or ventricular fibril-
ation, or appropriate implantable cardioverter-defibrillator
ICD) discharge. Two separate secondary end points were
redefined. A composite HF end point included unplanned
F hospital stay, progression to New York Heart Associ-
tion (NYHA) functional class III or IV status, or HF-
elated death. A composite arrhythmic end point included
ustained ventricular tachycardia or ventricular fibrillation,
ppropriate ICD discharge, or SCD. Start of follow-up was
efined as the date of the initial CMR. Patients were
ensored at the time of their first event or the time of their
ast clinical follow-up.
Kaplan-Meier curves were used to estimate the survival
istributions of the end points and to show the difference
n survival between those with and without fibrosis.
emographic, clinical, and scan characteristics were all
rst tested with univariate analysis, and all variables with
p value 0.05 were then taken forward to be considered
or inclusion in the multivariate model. The model was
onstructed with a forward selection procedure, with any
ariable that improved the likelihood ratio test statistic by
n amount equivalent to p  0.05 included. A Cox
roportional hazards model was used to estimate the
azard ratio (HR) for the presence or absence of fibrosis
nd to estimate the effect on the outcomes of increased
mounts of fibrosis. For each patient the predicted
robability of having an event at 1, 2, and 3 years was
alculated. This was done by obtaining the baseline
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September 7, 2010:867–74 Myocardial Fibrosis and Risk in HCMurvival from the Cox model for the cohort at each time
oint and calculating the increased risk associated with
ncreased levels of fibrosis. To test whether fibrosis was
n independent predictor of risk, a multivariate analysis
as performed (25). All analyses were performed with
tata version 10.1 (StataCorp, College Station, Texas).
esults
aseline characteristics. A total of 217 patients were
ollowed prospectively for 3.1  1.7 years, representing 671
atient years of follow-up. The baseline population charac-
eristics are summarized in Tables 1 and 2. Fibrosis was
resent in 63% of the total cohort. Within the fibrosis
roup, the mean percentage of fibrosis was 15.5% (range
.4% to 54.9%). Groups with and without fibrosis had
imilar mean ages and baseline risk factors but different
YHA status, left ventricular mass index, left atrial volume
ndex (LAVi), and maximum wall thickness.
Baseline Characteristics of 217 Patients With HTable 1 Baseline Characteristics of 217 Pa
No Fibrosis
(n  81)
Age at diagnosis, yrs 52.2 (14.8)
Age at baseline CMR, yrs 52.8 (14.6)
Male (%) 59 (72.8)
BSA (m2) 1.93 (0.23)
Ethnicity (%)
White 69 (85.2)
Black 7 (8.6)
Asian 3 (3.7)
Other/unknown 2 (2.5)
AF (%) 2 (2.5)
NYHA functional class (%)
I 47 (58.0)
II 28 (34.6)
III/IV 6 (7.4)
Mean NYHA functional class 1.52 (0.71)
Risk factors for SCD
Peak wall thickness, mm 17.5 (3.0)
Wall thickness 30 mm 0 (0)
Rest LVOTO 30 mm Hg 18 (22.2)
Family history of SCD 6 (7.4)
Syncope 12 (14.8)
Sustained VT/VF 1 (1.1)
Nonsustained VT (total) 3 (3.7)
Nonsustained VT (age 45 yrs) 2
Number of risk factors for SCD (%)
0 50 (61.7)
1 24 (29.6)
2 7 (8.6)
Beta-blockers (%) 23 (28.4)
Calcium antagonist (%) 7 (8.6)
Other antiarrhythmics (%) 6 (7.4)
According to presence or absence of fibrosis as detected by late gado
represents the t test comparison between fibrosis and no-fibrosis grou
AF  atrial fibrillation; BSA  body surface area; HCM  hypertroph
left ventricular end-diastolic volume; LVEF left ventricular ejection fr
outflow tract obstruction; NYHA  New York Heart Association functional cla
ventricular fibrillation.utopsy data. One patient with HCM who died underwent
utopsy. Assessment of the macroscopic appearance of the cut
urface of the heart showed focal fibrosis, which was confirmed
istologically with Picrosirius Red staining. There was excel-
ent agreement between the postmortem location and quantity
f fibrosis and LGE on antemortem CMR. We quantified the
mount of fibrosis with the FWHM technique in vivo and
ompared this with the amount of replacement fibrosis quan-
ified histologically at postmortem, with an excellent agree-
ent in the overall percentage of fibrosis quantified by the
MR technique versus histology. In this heart, LGE was
pecific for fibrosis rather than disarray (present in the septum)
Fig. 1). Representative patterns of fibrosis as imaged with
GE are shown in Figure 2.
rimary outcome. During follow-up, there were 9 cardio-
ascular deaths, 8 of which (89%) occurred in the fibrosis
roup. Overall, 40 of 217 (18.4%) patients reached the primary
nd point: 34 of 136 (25%) in the fibrosis group, and 6 of 81
With HCM
Fibrosis
(n  136)
Total
(n  217) p Value
50.4 (15.4) 51.1 (15.2) 0.40
53.2 (15.1) 53.2 (15.1) 0.84
94 (69.1) 153 (70.5) 0.56
1.92 (0.18) 1.92 (0.18) 0.74
123 (90.4) 192 (88.5) 0.002
0 (0) 7 (3.2)
12 (8.8) 15 (6.9)
1 (0.7) 3 (1.4)
9 (6.6) 11 (5.1) 0.18
52 (38.8) 99 (46.1) 0.01
58 (43.3) 86 (40.0)
24 (17.9) 30 (13.9)
1.80 (0.74) 1.69 (0.74) 0.01
23.3 (5.0) 21.1 (5.2) 0.001
12 (8.8) 12 (5.5) 0.006
39 (28.7) 57 (26.3) 0.30
19 (14.0) 25 (11.5) 0.14
23 (16.9) 35 (16.1) 0.695
5 (3.7) 6 (2.8) 0.29
16 (11.8) 19 (8.8) 0.04
4 6 NS
65 (47.8) 115 (53.0) 0.06
45 (33.1) 69 (31.8)
26 (19.1) 33 (15.2)
60 (44.1) 83 (38.3) 0.02
24 (17.7) 31 (14.3) 0.07
23 (16.9) 29 (13.4) 0.05
nhancement cardiovascular magnetic resonance (CMR). The p value
ues are mean  SD unless otherwise stated.
iomyopathy; LAV  left atrial volume; LV  left ventricular; LVEDV 
LVESV left ventricular end-systolic volume; LVOTO left ventricularCMtients
linium e
ps. Val
ic card
action;ss; SCD  sudden cardiac death; VT/VF  ventricular tachycardia/
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Myocardial Fibrosis and Risk in HCM September 7, 2010:867–747.4%) in the no-fibrosis group (HR: 3.4, 95% confidence
nterval [CI]: 1.4 to 8.1, p 0.006) (Fig. 3A). The breakdown
f events for the primary end point is shown in Table 3. In the
brosis group, the overall risk of the primary end point
ncreased with the percentage of fibrosis present (HR: 1.18/5%
brosis increase, 95% CI: 1.05 to 1.33, p  0.008) (Fig. 3B).
he presence and amount of fibrosis remained independent
redictors of the primary outcome after multivariable analysis
fibrosis  HR: 2.7, 95% CI: 1.01 to 7.1, p  0.046; fibrosis
HR: 1.15, 95% CI: 1.01 to 1.30, p 0.03). Hence, for every
% increase in fibrosis the risk of reaching the primary end
oint increases by 15%. Other variables that were found to be
ndependently associated with the primary outcome in the
ultivariate model were LAVi (HR: 1.016, 95% CI: 1.008 to
.024, p 0.001) and NYHA functional class (HR: 1.6, 95%
I: 1.07 to 2.31, p  0.021).
econdary outcomes. HF. Overall, 41 of 217 (19%) of the
ohort reached the secondary HF end point: 33 of 136
24.5%) in the fibrosis group, and 8 of 81 (9.9%) in the no
brosis group (HR: 2.51, 95% CI: 1.1 to 5.5, p  0.021)
Figure 1 Autopsy Correlation of Fibrosis With In Vivo LGE-CMR
Comparison of in vivo late gadolinium enhancement (LGE) images (A, B, white arr
and confirmed fibrosis on histology sections stained with Picrosirius red (D). CMRFig. 4A). In the fibrosis group, the overall risk increased oith the percentage of fibrosis present (HR: 1.16, 95% CI:
.03 to 1.31, p  0.017/5% fibrosis increase) (Fig. 4B).
oth the presence and amount of fibrosis remained signif-
cant predictors of HF outcome after multivariate analysis
fibrosisHR: 2.6, 95% CI: 1.08 to 6.5, p 0.033; fibrosis
HR: 1.21 95% CI: 1.06 to 1.37) p  0.004). Other
ariables that were found to be independently associated
ith HF outcomes included LAVi (HR: 1.021, 95% CI:
.01 to 1.03, p  0.001) and the presence of a left
entricular outflow gradient of 30 mm Hg (HR: 2.45,
5% CI: 1.2 to 4.9, p  0.013). In multivariate analysis,
fter adjustment for baseline differences in NYHA status,
he amount of fibrosis remained a significant predictor of
F outcomes (HR: 1.27, 95% CI: 1.02 to 1.6, p  0.035).
n addition, in subset analysis for patients in NYHA
unctional classes I and II with no previous HF hospital
tay, the presence and amount of fibrosis remained predic-
ive of the secondary HF end points (fibrosis  HR: 2.73,
5% CI: 1.2 to 6.3, p 0.019; fibrosis % HR: 1.16, 95% CI:
.01 to 1.34, per 5% increase, p  0.035). Furthermore, the
atching macroscopic assessment from autopsy (C),
diovascular magnetic resonance.ows) m
 carverall percentage of fibrosis was a stronger predictor in this
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September 7, 2010:867–74 Myocardial Fibrosis and Risk in HCMohort of HF outcomes than the presence of left ventricular
utflow tract obstruction (LVOTO) 30 mm Hg.
rrhythmic outcome. Of the entire cohort, 12 of 217
eached the secondary arrhythmic end point: 10 of 136
7.3%) in the fibrosis group, and 2 of 81 (2.5%) in the
o-fibrosis group (HR: 3.15, 95% CI: 0.69 to 14.4, p 
.138). Univariate predictors of this end point were the
resence of NSVT and the overall percentage of fibrosis.
one of the other standard clinical risk factors were
redictive in this cohort. The amount of fibrosis was
ignificantly associated with the outcome in univariate
nalysis (HR: 1.30, 95% CI: 1.05 to 1.61, p  0.014), but
n the multivariable analysis NSVT was the strongest
Figure 2 Representative Patterns and Severities of Fibrosis in
Patchy and focal insertion point fibrosis (A to C), with other focal areas of patchy
circumferential diffuse mid-wall fibrosis (D), primarily at the apex. (E to H) Increas
extensive inferoseptal fibrosis in F; extensive anterior and anteroseptal fibrosis in
trophic cardiomyopathy; other abbreviations as in Figure 1.
Baseline CMR Characteristics of 217 Patients WTable 2 Baseline CMR Characteristics of 21
CMR Parameters
No Fibrosis
(n  81)
LVEF, % 75.9 (8.4)
LVEDV, ml 130.6 (38.9)
LVESV, ml 33.8 (22.6)
LVEDV indexed, ml/BSA 67.5 (16.4)
LVESV indexed, ml/BSA 17.2 (10.5)
LV mass, g 179.8 (49.7)
LV mass indexed, g/BSA 93.2 (22.3)
LAV, ml 89.7 (33.1)
LAV indexed, ml/BSA 46.8 (16.6)
Fibrosis, mean % (range) 0
Values are mean  SD unless otherwise stated. According to presenc
t test comparison between fibrosis and no fibrosis groups.
Abbreviations as in Table 1.redictor, and after this no other variables were added to the
odel owing to the low event numbers.
iscussion
here are limited data on the prognostic significance of
brosis in patients with HCM. The main findings are that
he presence and severity of fibrosis are associated with a
reater risk of major adverse events.
Hypertrophic cardiomyopathy is an important cause of
CD throughout life and progressive HF and stroke in
lder patients. Established risk markers mainly focus on
dentifying those at risk of SCD (approximately 0.5%/year).
as Detected With LGE-CMR
ll fibrosis in the basal anteroeptal wall (A) and anterolateral wall (B). A more
verities of myocardial fibrosis with more diffuse insertion point fibrosis in E;
widespread anterolateral, septal, and inferoseptal fibrosis in H. HCM  hyper-
HCMtients With HCM
ibrosis
 136)
Total
(n  217) p Value
7 (11.6) 73.9 (10.6) 0.03
5 (35.9) 129.9 (37.0) 0.82
3 (21.4) 36.0 (21.9) 0.25
5 (16.7) 67.5 (16.5) 0.99
5 (11.2) 18.6 (11.0) 0.14
5 (85.6) 209.8 (77.7) 0.001
2 (41.3) 108.9 (37.4) 0.001
1 (57.5) 103.9 (51.0) 0.002
3 (28.5) 54.1 (25.4) 0.002
5 (1.4–54.9) 9.7 (0–54.9) NA
ence of fibrosis as detected by LGE-CMR. The p value represents theHCM
mid-wa
ing se
G; andith7 Pa
F
(n
72.
129.
37.
67.
19.
227.
118.
112.
58.
15.
e or abs
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Myocardial Fibrosis and Risk in HCM September 7, 2010:867–74Figure 3 Fibrosis and Development of Primary End Point
and Annual Probability of Primary End Point
(A) Fibrosis and development of primary end point. Kaplan-Meier unadjusted
estimates of freedom from reaching combined primary end point (cardiovascu-
lar death, unplanned cardiovascular admission, sustained ventricular tachycar-
dia or ventricular fibrillation, appropriate implantable cardioverter-defibrillator
discharge) in 217 hypertrophic cardiomyopathy (HCM) patients according the
presence or absence of fibrosis. (B) Annual probability of primary end point corre-
lating to amount of fibrosis. Predicted probability of reaching the combined primary
end point at 1, 2, and 3 years on the basis of the overall percentage of fibrosis
(broken and unbroken lines), plotted against the x-axis on the right. The bar
charts represent the overall percentage of patients with this amount of fibrosis,
plotted on the x-axis on the left. LGE  late gadolinium enhancement.CI  confidence interval; CV  cardiovascular; CVA  cardiovascular accide
VT/VF  ventricular tachycardia/ventricular fibrillation.Figure 4 Fibrosis and Development of HF
(A) Kaplan-Meier unadjusted estimates of freedom from reaching combined
heart failure (HF) end point (HF-related death, unplanned HF admission, deterio-
ration to New York Heart Association functional class III/IV) in 217 HCM patients
according the presence or absence of fibrosis. (B) Probability of HF on the
basis of annual risk and amount of fibrosis. Predicted probability of reaching
the combined HF end point at 1, 2, and 3 years on the basis of the extent of
fibrosis (broken and unbroken lines), plotted against the x-axis on the right.
The bar charts represent the overall percentage of patients with this amount of
fibrosis, plotted on the x-axis on the left. LGE  late gadolinium enhancement.Breakdown of Events Contributing to Overall MACE Ratein 217 HCM Pati With and Without FibrosisTable 3 Breakdown of Events C ntributing to Overall MACE Ratein 217 HCM Patients With and Without Fibrosis
Outcome
No Fibrosis
(n  81)
Fibrosis
(n  136)
Total
(n  217) HR 95% CI p Value
Primary outcome 6 (7.4) 34 (25.0) 40 (18.4) 3.367 1.406–8.063 0.006
CV mortality 1 (1.2) 8 (5.9) 9 (4.2) 4.452 0.548–36.204 0.163
Unplanned CV hospital stay 5 (6.2) 24 (17.7) 29 (13.4) 2.825 1.072–7.448 0.036
VT/VF 1 (1.2) 8 (5.9) 9 (4.2) 4.973 0.622–39.762 0.131
ICD discharge 0 (0) 2 (1.5) 2 (0.9) NA — —
Sudden death 1 (1.2) 1 (0.7) 2 (0.9) 0.648 0.041–10.360 0.759
HF death 0 (0) 6 (4.4) 6 (2.8) — — —
CVA death 0 (0) 1 (0.7) 1 (0.4) NA — —nt; HR  hazard ratio; ICD  implantable cardioverter-defibrillator;
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September 7, 2010:867–74 Myocardial Fibrosis and Risk in HCMowever, there remain many patients where additional risk
tratification would be beneficial, particularly those with a
ingle risk factor. In addition, there is limited guidance to
dentify those at risk of progressive HF, which affects up to
0% of patients (14). Understanding processes occurring at
he myocardial tissue level—in particular, fibrosis—might
rovide a novel marker to predict both arrhythmic and HF
utcomes. Fibrous tissue promotes re-entrant ventricular
rrhythmias and contributes to increased ventricular stiffness
26–29). In histopathological studies, there is an 8-fold
ncrease in the amount of matrix collagen in adults and
hildren who die suddenly from HCM compared with
ormal control subjects (8). This is also reflected in greater
evels of serum markers of collagen turnover (30). Micro-
copic fibrosis is greater in hearts of patients with the dilated
hase of HCM than in nondilated hearts (26).
It is only recently that fibrosis in HCM could be detected
oninvasively in vivo with the CMR LGE technique, where
adolinium-contrast agents accumulate in areas of intersti-
ial expansion due to fibrosis, which can then be imaged (7).
ibrosis detection by the LGE technique has prognostic
ignificance in ischemic heart disease and dilated cardiomy-
pathy (31,32). The importance in HCM is unclear, al-
hough we and others have shown an association with
arkers for SCD (12,33). It also seems to correlate with
ystolic dysfunction and the development of NSVT (10,14).
everal methods have been described to quantify the
mount of myocardial fibrosis. In this study we used an
stablished and validated method of quantification based on
he FWHM technique. Several groups have recently shown
hat this technique correlates accurately with ex vivo quan-
ification of fibrosis and has the best reproducibility (22–24).
ome groups have used an alternative method based on
hresholding with the use of silicon cutoff values of between
and 6 SDs above the remote noninjured myocardium and
n particular 6 SDs. Work by Spiewak et al. (24) has
emonstrated no significant difference between techniques
or quantifying fibrosis in HCM on the basis of 6 SDs and
WHM thresholding methods compared with visual anal-
sis, with the best intraobserver agreement noted for the
WHM method. The findings of this study suggest that
ither method of quantification is likely to be valid. Further
ork is ongoing to assess whether one method is more
ccurate, compared with histological validation in HCM.
The findings in this study indicate that CMR fibrosis
dentifies patients at increased risk of disease progression. Both
he presence and the amount of fibrosis are of independent
rognostic significance. The presence of fibrosis is associated
ith a 3.4-fold greater risk of major adverse events, and the risk
s proportional with increased amounts of LGE-detected
brosis. These results are predominantly driven by the devel-
pment of HF (2.5-fold increase in risk). This risk is indepen-
ent of baseline NYHA status. In this study, the prevalence of
VOTO was similar in both groups, and although it was
hown to be an independent predictor of the HF outcomes, it
as a weaker predictor than the amount of LGE and a similar ctrength predictor for the presence or absence of LGE.
egarding the potential that LVOTO might promote the
evelopment of LGE, this has not as yet been demonstrated in
ublished reports and would be the basis for further important
ork. It is likely that several factors contribute to the develop-
ent of fibrosis in HCM, a fact supported by the finding of
GE in patients without LVOTO and in apical HCM
henotypes. Although it is thought-provoking to highlight
hat 83% (10 of 12) of major arrhythmic events occurred in the
roup with fibrosis, this study was underpowered to show this
o be statistically significant. Both the overall percentage of
brosis and NSVT were important independent predictors of
ajor arrhythmic end points, but owing to the small numbers
f these events over the time course of this study, fibrosis
ercentage did not reach statistical significance after multiva-
iable analysis. This relationship to arrhythmic end points
ight prove to be more relevant over a longer-term follow-up.
t present, the data suggest the need for closer monitoring of
atients with HCM and fibrosis for the development of HF.
hat even small amounts of replacement fibrosis are associated
ith increased risk of development of HF might be a marker
f more significant underlying interstitial fibrosis. Further work
ill be required to identify whether early therapy with an
ntifibrotic agent has an impact. The findings do not, at
resent, support the routine deployment of an ICD on the
asis of the presence or amount of fibrosis per se. This is
onsistent with other recent work (34).
tudy limitations. Although this was a single-center study
n a tertiary hospital, this allowed for a consistent scanning
rotocol and close follow-up of all patients. To ensure a
epresentative cohort, consecutive HCM referrals from a
arge network of referring hospitals were recruited. Further
ork is required to identify whether these findings are
pplicable to a community-based population. The accrued
71 patient-years of follow-up was underpowered to assess
brosis incrementally to other risk factors for SCD, and
ngoing prospective follow-up in a larger cohort will be
equired. The LGE technique detects only focal fibrosis and
ot microscopic diffuse fibrosis. Patients with an ICD at
aseline were excluded from enrollment, owing to the
ontraindication for CMR. It is unclear how their inclusion
ould influence the present results, although other groups
ave previously shown that the incidence of fibrosis in this
igh-risk cohort to be higher than lower-risk populations.
urther work is required to determine whether specific patterns
nd locations of fibrosis correlate with differing outcomes.
onclusions
n vivo fibrosis detection by CMR is an independent predictor
f adverse outcome in HCM. As a novel marker it seems to
etect those at risk of progressive disease and might guide
pecific therapies for HF prevention and treatment. As a risk
actor for SCD, it is likely that longer follow-up in a larger
ohort will clarify the role of fibrosis detection.
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